ARTICLE | Clinical News
NT-300: Phase III started
April 29, 2013 7:00 AM UTC
Romark began a double-blind, placebo-controlled, international Phase III trial to compare twice-daily 600 mg NT-300 alone or in combination with twice-daily 75 mg oral Tamiflu oseltamivir for 5 days ...